English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

We thank Professor Kostev for his comments (1) on our manuscript that evaluated the contemporary prevalence of diabetic peripheral neuropathy (DPN) in 5,936 participants with type 1 diabetes (T1D) in the T1D Exchange Clinic Registry (2). As described, we found a DPN prevalence of 11% as defined by the Michigan Neuropathy Screening Instrument Questionnaire (MNSIQ) (2). Our study highlighted several nonglycemic risks factors including hypertriglyceridemia (odds ratio [OR] 1.03, 95% CI 1.01, 1.05) and smoking (OR 1.83, 95% CI 1.18, 2.82) and other complications including retinopathy (OR 1.46, 95% CI 1.14, 1.88) and cardiovascular disease (CVD) (OR 1.73, 95% CI 1.24, 2.42) (2).We elected to use the MNSIQ because it is a simple, noninvasive measure of DPN that has …

diabetes care

Response to Comment on Mizokami-Stout et al. The Contemporary Prevalence of Diabetic Neuropathy in Type 1 Diabetes: Findings From the T1D Exchange. Diabetes Care 2020;43:806–812